SEC Form 6-K filed by FSD Pharma Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of: August 2024

Commission File Number: 001-39152

199 Bay St., Suite 4000

Toronto, Ontario M5L 1A9, Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

INCORPORATION BY REFERENCE

This Form 6-K and Exhibit 99.1 attached hereto are incorporated by reference into the Registrant’s Registration Statement on Form F-3 (SEC File No. 333-276264), including any prospectuses forming a part of such Registration Statement.

EXPLANATORY NOTE

On August 15, 2024, Quantum BioPharma Ltd., formerly known as FSD Pharma Inc. (the “Company”) issued a press release titled “FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation – Trading under New Ticket Symbol “QNTM.”  A copy of the press release is furnished herewith as Exhibit 99.1

Exhibit 99.1 is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-276264), including any prospectuses forming a part of such Registration Statement, and shall be deemed to be a part thereof from the date on which the report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXHIBIT INDEX